Jan. 27 at 10:14 PM
$IMMX reclaiming the
$6 handle today shows buyers stepping back in ahead of a catalyst‑heavy 2026.
Momentum is tightening, volume is steady, and the chart is setting up for another test of the mid‑6s.
NXC‑201 continues to be the core value driver, with strong clinical data and a clean safety profile highlighted in recent coverage.
52‑week range still stretches to
$7.73, so there’s room for a retest if sentiment stays positive.
Market cap remains sub-
$300M, which keeps IMMX in the “undervalued biotech” conversation as long as trial progress stays on track.
Levels I’m Watching
Support:
$5.50–
$5.70
Breakout Zone:
$6.20–
$6.40
Bull Case Target: Retest of
$7+ range if catalysts line up
IMMX is showing strength while the broader biotech tape is mixed. 🎸🎵
